Evidence map›Paper›PMID 24360877›Full record

ArticleThe Annals of thoracic surgery2014

Impact of extracardiac vascular disease on vein graft failure and outcomes after coronary artery bypass surgery.

Ralf E Harskamp, John H Alexander, Phillip J Schulte, W Schuyler Jones, Judson B Williams, Michael J Mack, Eric D Peterson, C Michael Gibson, Robert M Califf, Nicholas T Kouchoukos and 3 more

Abstract read
In one paragraph

Article in The Annals of thoracic surgery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Ralf E HarskampDuke Clinical Research Institute, Durham, North Carolina; Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
John H AlexanderDuke Clinical Research Institute, Durham, North Carolina.
Phillip J SchulteDuke Clinical Research Institute, Durham, North Carolina.
W Schuyler JonesDuke University Medical Center, Durham, North Carolina.
Judson B WilliamsDuke University Medical Center, Durham, North Carolina.
Michael J MackCardiopulmonary Research Science and Technology Institute, Dallas, Texas.
Eric D PetersonDuke Clinical Research Institute, Durham, North Carolina.
C Michael GibsonPERFUSE Angiographic Laboratory, Boston, Massachusetts.
Robert M CaliffDuke Translational Medicine Institute, Durham, North Carolina.
Nicholas T KouchoukosMissouri Baptist Medical Center, St. Louis, Missouri.
T Bruce FergusonEast Carolina University, Greenville, North Carolina.
Robbert J de WinterDepartment of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Renato D LopesDuke Clinical Research Institute, Durham, North Carolina. Electronic address: renato.lopes@duke.edu.
Clinical Research Institute · USAcademic Medical Center · NLDuke Medical Center · USCardiopulmonary Research Science and Technology Institute · USEast Carolina University · USMissouri Baptist Medical Center · US

Funding

Core Clinical Centers for the CTSNUM1HL088953 · NHLBI · DUKE UNIVERSITY · PI SMITH, PETER K · 2013 to 2017
$2.5M
NHLBI NIH HHS UM1 HL088953
6 · The paper itself

Abstract

backgroundWhile extracardiac vascular disease (ECVD), defined as a history of peripheral vascular disease (PVD) or cerebrovascular disease (CBVD), is common in patients undergoing coronary artery bypass graft (CABG) surgery, there are limited data available on the association between ECVD, vein graft failure (VGF), and clinical outcomes.

methodsUsing data from the Project of Ex-vivo Vein Graft Engineering via Transfection IV (PREVENTIV) trial (n = 3,014), 1-year angiographic follow-up and 5-year clinical outcomes (death, myocardial infarction, and revascularization) were determined in patients with and without ECVD. Logistic regression was used to assess risk of VGF. Generalized estimating equations methods were used to account for correlations in a graft-level analysis. Kaplan-Meier estimates and Cox hazards regression were used to compare clinical outcomes. We similarly explored the association of the individual components CBVD and PVD with both VGF and clinical outcomes in an additive model.

resultsPatients with ECVD (n = 634, 21%) were older, more commonly female, and had more comorbidities, lower use of internal thoracic artery grafting, and overall worse graft quality than patients without ECVD. VGF rates tended to be higher (patient-level: odds ratio [OR]: 1.23, 95% confidence interval [CI] 0.96 to 1.58, p = 0.099; graft-level: OR: 1.23, 95% CI: 1.00 to 1.53, p = 0.053) in patients with ECVD. VGF rates were significantly higher among CBVD patients (OR: 1.42, 95% CI: 1.03 to 1.97, p = 0.035; graft-level: OR: 1.40, 95% CI: 1.06 to 1.85, p = 0.019). Patients with ECVD had a higher risk of death, myocardial infarction, or revascularization 5 years after CABG surgery (hazard ratio [HR]: 2.96, 95% CI: 2.02 to 4.35, p < 0.001). This relationship was driven by the subset of patients with PVD (HR = 3.32, 95% CI: 2.16 to 5.09, p < 0.001) and not by those with CBVD (HR = 1.10, 95% CI: 0.88 to 1.37, p = 0.40).

conclusionsECVD is common among patients undergoing CABG surgery and is associated with similar short-term but increasingly worse long-term clinical outcomes. This higher risk may be partly, but not exclusively, due to higher rates of VGF among these patients.

Indexed as

Coronary Artery BypassAgedCerebrovascular DisordersCoronary DiseaseFemaleHumansMaleMiddle AgedPeripheral Vascular DiseasesRetrospective StudiesRisk FactorsTreatment FailureTreatment OutcomeVeins

Identifiers

PMID24360877
PMCPMC4324323
OpenAlexW2160474716

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.